Comparative Pharmacology
Head-to-head clinical analysis: ELELYSO versus ELFABRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELELYSO versus ELFABRIO.
ELELYSO vs ELFABRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
1 mg/kg intravenously over 2 hours every 2 weeks.
None Documented
None Documented
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy